Nurix Therapeutics (NRIX) Cash & Current Investments (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash & Current Investments data on file, last reported at $540.7 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $540.7 million, down 1.63% year-over-year; the trailing twelve-month figure through Feb 2026 was $540.7 million (down 1.63% YoY), and the FY2025 annual result was $592.9 million, down 2.73% from the prior year.
• Cash & Current Investments retreated to $540.7 million in Q1 2026 per NRIX's latest filing, from $592.9 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $609.6 million in Q4 2024 and troughed at $244.0 million in Q1 2024.
• A 5-year average of $391.8 million and a median of $344.5 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments slipped 24.86% in 2023, then surged 125.29% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $309.1 million in 2022, then fell by 6.87% to $287.9 million in 2023, then jumped by 111.73% to $609.6 million in 2024, then retreated by 2.73% to $592.9 million in 2025, then declined by 8.81% to $540.7 million in 2026.
• Business Quant data shows NRIX's Cash & Current Investments at $540.7 million in Q1 2026, $592.9 million in Q4 2025, and $428.8 million in Q3 2025.